The ultrasound system developer, backed by investors including GE, has now raised more than $122m, after securing $50m in its latest round.

The pharmaceutical company raised $32.7m after floating at a price far below its range, while Janssen Pharmaceutica took a 17% stake.

UrgentRX, which develops fast-acting over-the-counter flavoured powder medications, has raised $17.5m in series C funding.

Array Biopharma is among the shareholders of the cancer therapeutics developer after striking a development deal in July last year.

Physicians Interactive bought the health community platform with financing supplied by existing investor Merck, through its Global Health Innovation Fund.

The pharmaceutical company has committed the capital to a healthcare venture fund formed by investment firm Sectoral Asset Management.

The Novo Nordisk-backed cancer drug developer has set a $75m target for its initial public offering and will use the proceeds to fund further research.

PierianDx will commercialise diagnostic tools for personalised medicine.